PDL BioPharma Inc. (PDLI)

2.56
NASDAQ : Health Technology
Prev Close 2.55
Day Low/High 2.47 / 2.57
52 Wk Low/High 2.25 / 3.89
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 114.20M
Market Cap 291.22M
EPS -0.50
P/E Ratio 8.79
Div & Yield N.A. (N.A)

Movers Roundup: JC Penney, Accenture

Movers roundup: JC Penney rises on upbeat analyst, improving outlook; Accenture plunges

PDL Shares Rise On Outlook, Analyst Upgrade

PDL BioPharma shares rise on revenue outlook, Lazard Capital analyst upgrade

Google, Amgen, Tyson Foods Are Big Movers

Google, Amgen, Tyson Foods, KB Home, Johnson Controls are among big market movers Friday

Facet Shares Rise On Funding, Outlook

Facet Shares Rise On Funding, Outlook

Facet Biotech shares rise on positive funding outlook, advancing product pipeline

Top NYSE Short-Squeeze Opportunities

These heavily shorted NYSE stocks could surge higher on any positive catalyst.

Health Care Winners & Losers: Alkermes

Health Care Winners & Losers: Alkermes

An analyst gives health care top sector ratings.

TSC Ratings' Updates: Tiffany

TSC Ratings' Updates: Tiffany

Legg Mason, Discover, Tiffany and VF Corp. are downgraded; PDL Biopharma is upgraded.

Health Winners & Losers: Luminex

Health Winners & Losers: Luminex

Accuray falls 16%.

Health Winners & Losers: Nuvelo

Nuvelo rises on merger news.

Health Winners & Losers: Bristol, ImClone

Health Winners & Losers: Bristol, ImClone

Bristol and ImClone shares fall as more drama unfolds surrounding their potential merger. King Pharmaceuticals' shares are down after it increased its bid for Alpharma.

Health Winners & Losers: Eli Lilly

The company's shares were down slightly after it agreed to buy rights to a dairy cow supplement from Monsanto.

Bristol Myers, PDL Team on Cancer Drug

The two drugmakers signed a development and commercialization agreement for an early stage prospective treatment for multiple myeloma.

Friday's Winners & Losers: UAL

Friday's Winners & Losers: UAL

United Airlines' operator's shares are up 8.2% after the company announces new charges for checked bags.

Health Winners & Losers: Maxygen

Health Winners & Losers: Maxygen

Maxygen slides on news Amgen was granted a patent that may affect Maxygen's MAXY-G34, a possible treatment for chemotherapy-induced neutropenia.

Wednesday's Winners & Losers: Nortel Networks

Wednesday's Winners & Losers: Nortel Networks

Shares gain 13.6% after The Wall Street Journal reports that the company is developing a new broadband technology.

Health Winners & Losers: Merck

Merck slides as UBS lowers its price target.

Health Winners & Losers: Geron

Health Winners & Losers: Geron

Geron takes back some of the previous day's big loss.

Tuesday's Analysts' Upgrades, Downgrades

Tuesday's Analysts' Upgrades, Downgrades

See who made what calls.

Friday's Health Winners & Losers

PDL BioPharma surges on spinoff news.

Wednesday's Winners & Losers: Jabil Circuit

Shares fall 16% after the company gives guidance below expectations.

Wednesday's Health Winners & Losers

Big biotechs Amgen, Biogen and Genentech see modest gains.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Exact Sciences climbs on a nod from the American Cancer Society.

Wednesday's Health Winners & Losers

PDL BioPharma plummets after pulling plans for a company sale.

PDL BioPharma Pulls Sale Plans

Shares plunge after the company fails to find a buyer.

PDL BioPharma Sets Another Asset Sale

The biotech firm plans to sell its antibody manufacturing plant for $240 million.

PDL BioPharma Sale Fails to Please

The biotech firm sells off its cardiovascular assets for a price below expectations.

Stock Upgrades, Downgrades From TheStreet.com Ratings

Stock Upgrades, Downgrades From TheStreet.com Ratings

NYSE Euronext, Wesco Financial and Foundation Coal upgraded; PDL BioPharma and Knight Transport downgraded.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

PDL BioPharma climbs on an upgrade.

Biotech Notebook: Xoma, Medivation, Delcath

Biotech Notebook: Xoma, Medivation, Delcath

Xoma's apparent lack of interest in a buyout may not serve investors in the near term.

Biotech Notebook: Nastech, Amgen, PDL BioPharma

Skeptics of Nastech's nasal spray have gotten their due.

TheStreet Quant Rating: C- (Hold)